[ORGANIZATION]
CagriSema
Featured in 5 tracked stories · first seen
Situations
Novo Nordisk pivots strategy to counter patent cliff
107 clusters · 526 sources · last updated
Latest: Novo Nordisk unveils 2030 growth strategy amid patent concerns
Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide, the active ingredient in Ozempic and Wegovy. During a 2026 Capital Markets Day in Lond
Also covered in
-
Novo Nordisk CagriSema shows higher weight loss than Mounjaro in Phase 3 study
[HEALTH] · 2 sources ·